Table 4 Comparison of clinical, laboratory and radiological data of studied cases (n = 50) before and 3 months after Zn supplementation
Before Zn | After Zn | z | p | |
|---|---|---|---|---|
Height SDS | −3.12 ± 0.2 | −1.87 ± 0.1 | 6.76 | 0.033* |
(−2.15- -4.21) | (−2.0- -3.11) | |||
Weight SDS | -1.88 ± 0.62 | -1.72 ± 0.51 | 1.83 | 0.21 |
(-2.01- +0.55) | (-2.05- + 0.66) | |||
BMI (kg/m2) | 16.41 ± 0.56 | 16.58 ± 0.22 | 1.59 | 0.11 |
(14.33-18.12) | (14.91-18.42) | |||
BMI SDS | -1.77 ± 0.41 | -1.58 ± 0.32 | 1.80 | 0.26 |
(-2.10- -0.78) | (-0.91- -1.95) | |||
Serum Zn (μg/dl) | 56.76 ± 7.9 | 148.25 ± 15.4 | 8.29 | <0.001*** |
(37.52-93.11) | (77.55-226.13) | |||
Peak GH after insulin stimulation (ng/ml) | 10.65 ± 2.01 | 12.10 ± 1.13 | 2.10 | 0.081 |
(7.61-13.20) | (8.90-14.82) | |||
Peak GH after clonidine stimulation (ng/ml) | 11.14 ± 1.41 | 12.99 ± 1.22 | 1.15 | 0.090 |
(6.92-14.11) | (8.90-14.82) | |||
IGF-1 (ng/ml) | 96.72 ± 11.5 | 177.50 ± 9.06 | 7.12 | <0.010** |
(36.52-115.69) | (42.65-213.66) | |||
IGF-1 SDS | -2.46 ± 0.11 | -0.91 ± 0.43 | 9.16 | <0.010** |
(-3.22- +0.55) | (-2.95 - +1.10) | |||
IGFBP-3 (ng/ml) | 2436.12 ± 392 | 2856.30 ± 411 | 5.90 | 0.042* |
(1195.45-3898.15) | (1341.10-3912.51) | |||
-BA (years) | 3.7 ± 1.05 | 4.12 ± 1.32 | 1.25 | 0.081 |
(1.81-9.25) | (2.13-9.81) | |||
-BA SDS | -1.7 ± 1.14 | -1.5 ± 1.21 | 0.13 | 0.35 |
(-2.44 - +0.22) | (-2.10- + 0.65) |